GSK plc Releases 2022 Annual Report Focusing on Biopharma and Growth

GSK plc has issued its 2022 annual report, documenting a landmark year for the company. The report emphasizes GSK's transformation into a fully focused biopharma enterprise following the demerger of its consumer healthcare business, Haleon, in July. The company reported strong financial performance, including revenue growth and a solid operating profit.

The company is now placing a significant emphasis on research and development, leveraging the science of the immune system, human genetics, and advanced technologies. GSK's performance was influenced by its vaccines and specialty medicines business areas. The annual report underscores a commitment to a step-change in growth and performance by 2026, aiming to reach more patients with new and innovative products.

In research and development, GSK has strengthened its late-stage pipeline with new approvals and positive clinical data readouts. The company also undertook several strategic acquisitions and collaborations to bolster its position in medicine and vaccine research. GSK's report also details the company's responsible business strategies, covering ESG factors and contributing to advancing health.

Financial results for 2022 showed a turnover of £29.3 billion, a continuing operating profit of £6.4 billion, and earnings per share from continuing operations of 110.8 pence. Sales from innovation, including products launched in the last five years, amounted to £12.7 billion. The company is committed to enhancing its reporting on ESG metrics and is on track to meet its targets.